CIK 0001463361
UBX Unity Biotechnology, Inc.
Insider trading from SEC Form 4. Last filing Apr 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at Unity Biotechnology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Anirvan Ghosh Chief Executive Officer sell | $100k 96,797 shares | -39% | - | |
| 20Weak | Alexander Hieu Nguyen CLO and Head of Ops sell | $18k 17,852 shares | -27% | - | |
| 22Weak | Lynne Marie Sullivan CFO & Head of Corp. Dev. sell | $23k 21,867 shares | -18% | - | |
| 5Weak | Anirvan Ghosh Chief Executive Officer sell | $1,432 642 shares | -1% | - | |
| 20Weak | Anirvan Ghosh Chief Executive Officer sell | $557 432 shares | -1% | - | |
| 10Weak | Alexander Hieu Nguyen Chief Legal Officer sell | $192 149 shares | -1% | - | |
| 17Weak | Lynne Marie Sullivan CFO & Head of Corp. Dev. sell | $175 136 shares | -0% | - |
Transactions
The last 12 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | Anirvan Ghosh Chief Executive Officer | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -96,797 | $1.03 | $100k | 153,454 | Apr 3, 2025 |
| Apr 2, 2025 | Alexander Hieu Nguyen CLO and Head of Ops | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -17,852 | $1.03 | $18k | 48,753 | Apr 3, 2025 |
| Apr 2, 2025 | Lynne Marie Sullivan CFO & Head of Corp. Dev. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -21,867 | $1.03 | $23k | 98,905 | Apr 3, 2025 |
| Mar 28, 2025 | Anirvan Ghosh Chief Executive Officer | AGrant or award Common Stock, $0.0001 par value | +175,000 | $0.00 | $0 | 250,251 | Mar 31, 2025 |
| Mar 28, 2025 | Anirvan Ghosh Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +286,000 | $0.00 | $0 | 286,000 | Mar 31, 2025 |
| Mar 8, 2025 | Yehia Hashad director | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Mar 10, 2025 |
| Feb 4, 2025 | Anirvan Ghosh Chief Executive Officer | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -642 | $2.23 | $1,432 | 75,251 | Feb 5, 2025 |
| Jan 22, 2025 | Anirvan Ghosh Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Jan 23, 2025 |
| Jan 6, 2025 | Federico Grossi Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 7, 2025 |
| Nov 4, 2024 | Anirvan Ghosh Chief Executive Officer | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -432 | $1.29 | $557 | 75,893 | Nov 6, 2024 |
| Nov 4, 2024 | Alexander Hieu Nguyen Chief Legal Officer | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -149 | $1.29 | $192 | 24,723 | Nov 6, 2024 |
| Nov 4, 2024 | Lynne Marie Sullivan CFO & Head of Corp. Dev. | SOpen-market sale Common Stock, $0.0001 par value10b5-1 | -136 | $1.29 | $175 | 55,925 | Nov 6, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Anirvan GhoshChief Executive Officer
- Federico GrossiChief Medical Officer
- Yehia Hashadofficer, director
- Alexander Hieu NguyenCLO and Head of Ops
- Lynne Marie SullivanCFO & Head of Corp. Dev.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.